A study of the inconsistency of molecular typing in primary tumor and axillary lymph node metas-tasis of breast cancer
- Author:
- No author available
- Journal Title:
- China Clinical Practical Medicine
- Issue:
- 5
- DOI:
- 10.3760/cma.j.issn.1673-8799.2017.05.007
- Key Word:
- 乳腺癌;原发灶;腋窝淋巴结转移灶;分子分型;化学治疗;内分泌治疗;Breast cancer;Primary focus;Axillary lymph node metastasis;Molecular typing;Chemotherapy;Hormonal therapy
Abstract： Objective To investigate the value of molecular typing in primary tumor and axillary lymph node metastasis of breast cancer.Methods A total of 428 cases of female patients with unilateral breast cancer with axillary lymph node metastasis were selected from January 2011 to January 2016.ER, PR,Her-2 and Ki67 were detected by immunohistochemistry in primary tumor and axillary lymph node me-tastasis.Results Molecular typing of primary tumor and axillary lymph node metastases was inconsistent in 31 patients (31/428),luminal A of primary tumors in 14 cases,luminal B of primary tumors in 10 cases, while 4 cases of Her-2 over-expression and 3 cases of triple negative breast cancer in axillary lymph node metastases.Conclusion There was an inconsistency in primary tumor and axillary lymph node metastasis of some breast cancer.Immunohistochemistry for primary tumor and axillary lymph node metastasis of breast cancer associated with axillary lymph node metastasis should routinely carried out.Based on molecular typ-ing of primary tumor and axillary lymph node metastasis to develop individualized treatment programs,pa-tients could benefit from it.
- [1]郑莹,吴春晓,张敏璐.乳腺癌在中国的流行状况和疾病特征[J].2013,(8).
- [2]姚自翔,金梁斌,孔令泉,等.乳腺癌原发灶与同期腋淋巴结转移灶雌、孕激素受体和人类表皮生长因子受体2的表达差异研究进展[J].2014,(2).
- [3]刘钟芬,陈创,姚晓莉,等.乳腺癌不同分子分型的临床病理特点及预后分析[J].2016,(22).
- [4]莫雪莉.HER2阳性乳腺癌靶向治疗历程[J].2015,(5).
- [5]唐金海,陈伟贤.乳腺癌分子分型及其指导下的个体化治疗[J].2013,(3).
- [6]李惠平.不同分子类型乳腺癌的治疗策略和治疗后管理[J].2016,(12).
- [7]张敏(综述),张瑾(审校).三阴性乳腺癌分子分型与异质性的研究进展[J].2016,(7).
- [8]徐兵河.要重视乳腺癌的规范化治疗[J].2016,(9).
- [9]邓淼,刘江波,张婷,等.乳腺癌腋窝淋巴结状态与分子病理特征的关系及临床意义[J].2016,(12).
- [10].Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: A single-institution analysis[J].2013,24(1).
- [11]Freedman,O.C.,Amir,E.,Coleman,R.E.,etc.Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies[J].2012,38(6).
- [12]Lindstr?m,L.S.,Karlsson,E.,Wilking,U.M.,etc.Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression[J].2012,30(21).
- [13]Gullu I,Altundag K,Sari E,etc.Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer.[J].2011,28(1).
- [14]L, BENITEZ SOTO.[Breast cancer statistics].[J].1954,22(11).
- [15]Kassam,F.,Laupacis,A.,Clemons,M.,etc.Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer[J].2012,30(6).
- [16]赵海波,程雪雁,刘金君,等.乳腺癌原发灶与腋淋巴结转移灶ER和PR及c-erbB-2表达的对照研究[J].2011,(8).
- [17]Goldhirsch A,Wood WC,Coates AS,etc.Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.[J].2011,22(8).
- [18]Tawfik,K.,Kimler,B.F.,Davis,M.K.,etc.Ki-67 expression in axillary lymph node metastases in breast cancer is prognostically significant[J].2013,44(1).
- [19]Mittendorf,E.A.,Tokuda,Y.,Palla,S.L.,etc.Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors[J].2012,30(6).
- [20]刘琪,左文述,王新昭,等.乳腺癌原发灶和淋巴结转移灶激素受体及HER-2与Ki-67表达相关性分析[J].2013,(15).